ICD-10 Code A30.2 | Borderline tuberculoid leprosy Symptoms, Diagnosis, Billing

Borderline tuberculoid leprosy is a form of leprosy characterized by a moderate immune response to Mycobacterium leprae, leading to skin lesions and nerve damage. Accurate coding with ICD-10 Code A30.2 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that patients receive appropriate care and resources.

What is ICD-10 Code A30.2 for Borderline tuberculoid leprosy?

ICD-10 Code A30.2 represents Borderline tuberculoid leprosy, a subtype of leprosy where patients exhibit a mix of immune responses. This code is used in clinical documentation and billing when diagnosing patients with this condition, ensuring accurate representation of the disease for treatment planning and epidemiological tracking.

ICD-10 Code A30.2 – Clinical Definition and Explanation of Borderline tuberculoid leprosy

Borderline tuberculoid leprosy is caused by the bacterium Mycobacterium leprae, leading to skin lesions and peripheral nerve damage. It requires medical attention due to its potential for complications and transmission. Early diagnosis and treatment are crucial for effective management.

Key Clinical Features:

• Presence of hypopigmented skin lesions with well-defined borders.
• Nerve involvement leading to sensory loss or weakness.
• Possible systemic symptoms such as fever or malaise.
• Variable immune response, with some patients showing signs of recovery.

ICD-10 Code A30.2 for Borderline tuberculoid leprosy – SOAP Notes & Clinical Use

ICD-10 Code A30.2 is utilized in SOAP notes to document the patient's symptoms, assessment findings, and treatment plans. It is relevant in both acute and chronic care settings, ensuring comprehensive patient management and accurate billing.

What Does ICD-10 Code A30.2 for Borderline tuberculoid leprosy Mean in SOAP Notes?

In SOAP notes, ICD-10 Code A30.2 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Borderline tuberculoid leprosy. This ensures continuity of care, supports billing, and meets EHR documentation standards.

Treatment Options for ICD-10 Code A30.2 – Borderline tuberculoid leprosy

Borderline tuberculoid leprosy requires prompt treatment to prevent complications and transmission. Hospitalization may be necessary for severe cases.

Antibiotic Therapy:

• Rifampicin: 600 mg once monthly.
• Dapsone: 100 mg daily.
• Clofazimine: 300 mg once monthly and 50 mg daily.

Supportive Care:

• Regular monitoring of skin lesions and nerve function.
• Pain management for neuropathic symptoms.
• Patient education on skin care and self-examination.

Infection Control:

• Isolation precautions during the initial treatment phase.
• Education on transmission and prevention methods.
• Regular follow-up to monitor for new cases in the community.

How to Document Symptoms of Borderline tuberculoid leprosy (ICD-10 A30.2) in SOAP Notes

Subjective:

• Patient reports numbness and tingling in hands and feet.
• Noticed skin lesions developing over the past few months.
• Experiencing occasional fever and fatigue.

Objective:

• Skin examination reveals hypopigmented lesions on extremities.
• Neurological exam shows decreased sensation in affected areas.
• Vital signs stable; no acute distress noted.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Borderline tuberculoid leprosy (ICD-10 Code A30.2)

Assessment:

• Diagnosis: Borderline tuberculoid leprosy, moderate severity.
• ICD-10 Code: A30.2.
• Contributing factors: Possible exposure to infected individuals.

Plan:

• Initiate treatment with Rifampicin and Dapsone.
• Schedule follow-up in one month to assess treatment response.
• Educate patient on skin care and monitoring for new lesions.

Treatment & Plan Section for ICD-10 Code A30.2 – Borderline tuberculoid leprosy

• First-line pharmacologic treatments include Rifampicin and Dapsone.
• Non-pharmacologic strategies involve patient education on skin care.
• Monitoring includes regular follow-up appointments to assess treatment efficacy.
• Consider referral to a specialist for complex cases or complications.

Using ICD-10 Code A30.2 for Borderline tuberculoid leprosy in Billing & SOAP Note Compliance

• Select accurate subcodes based on clinical severity or complications.
• Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
• Ensure treatment plans align with clinical guidelines to support justified billing.
• List CPT codes commonly billed with ICD-10 Code A30.2 based on standard practices.

Related ICD-10 Codes Often Used with Borderline tuberculoid leprosy

• A30.0 – Lepromatous leprosy
• A30.1 – Tuberculoid leprosy
• A30.3 – Indeterminate leprosy
• A30.9 – Leprosy, unspecified

ICD-10 Code A30.2 in Medical Billing and Insurance for Borderline tuberculoid leprosy

ICD-10 Code A30.2 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.

Billing Notes:

• Ensure documentation includes detailed patient history and clinical findings.
• Use A30.2 in settings where leprosy is diagnosed or treated.
• Highlight key chart elements such as treatment plans and follow-up care.

Common CPT Pairings: